Teduglutide, a GLP-2 analog, regenerates intestinal tissue in short bowel syndrome patients, reducing diarrhea by 700 g/day and decreasing dependence on IV nutrition in Phase III trials.
~700 g/dayTeduglutide reduced diarrhea output by approximately 700 grams per day in a Phase II study — a clinically meaningful improvement for patients who may produce liters of liquid stool daily
What the researchers found
Teduglutide, a GLP-2 analog, promotes intestinal mucosal growth and restores absorptive function in patients with short bowel syndrome (SBS), reducing their dependence on intravenous parenteral nutrition (PN). In a Phase II study, teduglutide reduced diarrhea by approximately 700 g/day and fecal energy losses by about 0.8 MJ/day over 3 weeks. Two Phase III randomized placebo-controlled 24-week trials confirmed these results, showing significant improvements in intestinal fluid absorption.
The drug works by enhancing the structural and functional integrity of remaining intestine — essentially making the surviving gut more efficient at absorbing nutrients and fluid. This translated to measurable reductions in the volume and frequency of parenteral support needed, significantly improving patients' quality of life.
Why it matters
Short bowel syndrome patients who can't absorb enough nutrients depend on IV nutrition (parenteral support) delivered through a central line — a lifesaving but burdensome treatment that carries risks of bloodstream infections, blood clots, and liver disease. Teduglutide is the first drug to address the root problem by regenerating intestinal tissue and improving absorption, potentially freeing patients from some or all of their IV nutrition dependence.
The numbers in context
~700 g/day diarrhea reduction · ~0.8 MJ/day fecal energy loss reduction · 24-week Phase III trials · 2 randomized placebo-controlled trials · up to 24 weeks safety data
How the study worked
Review covering teduglutide's mechanism of action, Phase II metabolic balance study results, and two Phase III randomized, placebo-controlled, 24-week clinical trials in patients with short bowel syndrome and intestinal failure.
Who was studied
Patients with short bowel syndrome and intestinal failure requiring parenteral support (IV nutrition)
What this study cannot tell us
Studies covered up to 24 weeks in duration — long-term safety and efficacy data (years of treatment) were not yet available at time of publication. The review was published before FDA approval, so post-marketing safety data is not included. Teduglutide promotes mucosal growth, raising theoretical concerns about intestinal polyps that require ongoing monitoring.
How to read the evidence
This review covers Phase II and Phase III randomized placebo-controlled trial data published in a peer-reviewed gastroenterology journal. The evidence is strong — teduglutide was subsequently FDA-approved based on these and additional studies.
When this study was published
Published in 2012 in Therapeutic Advances in Gastroenterology, before teduglutide's FDA approval (December 2012). The trial data described here directly supported regulatory approval. Years of post-marketing experience have since confirmed the safety and efficacy profile.
The bigger picture
GLP-1 gets all the headlines for weight loss, but its sibling GLP-2 has its own revolutionary application. Teduglutide (brand name Gattex/Revestive) was subsequently FDA-approved and represents the first drug that actually regrows intestinal tissue. For the short bowel syndrome community — roughly 10,000-20,000 patients in the US — it changed the treatment paradigm from managing a damaged gut to regenerating it. The success of teduglutide also validates GLP-2 as a therapeutic target for other intestinal conditions.
Questions still open
- Can teduglutide eventually allow some short bowel syndrome patients to completely stop parenteral nutrition?
- What is the long-term safety profile regarding intestinal polyp formation with chronic mucosal growth stimulation?
- Could GLP-2 analogs benefit other intestinal conditions like Crohn's disease or radiation enteritis?
Common questions
What is short bowel syndrome and why is it so serious?
How does teduglutide help the gut regrow?
Read the original research
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.
Therapeutic advances in gastroenterology, 5(3), 159-71
Citation
Jeppesen, Palle Bekker. (2012). Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.. Therapeutic advances in gastroenterology, 5(3), 159-71. https://doi.org/10.1177/1756283X11436318